Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Investigating the role of type-II innate lymphoid cells in allergic asthma
EF 2019-20
Résumé
"Emerging evidence suggests that eosinophilic asthma (EA) may be mediated by type-II innate lymphoid cells (ILC2s). Inflammatory cytokines produced by ILC2s promote eosinophil maturation. In EA, eosinophils migrate to the lungs and cause inflammation, driving pathogenesis. Corticosteroids are typically used to treat EA. However, 5-10% of asthmatics are resistant to this treatment and thus alternative therapeutics need to be developed. Recent work suggests that ILC2s can become resistant to steroids in the presence of specific cytokines. Thus, it is hypothesized that ILC2s may be responsible for the steroid insensitivity observed in some EA patients and that targeting of this cell population for inhibition could represent a novel therapeutic avenue for EA treatment.Currently, it is unknown which cytokines may promote ILC2 steroid resistance, and whether these cytokines influence ILC2 surface marker expression. Peripheral blood, sputum and bronchoalveolar lavage fluid collected from human subjects with EA will be analyzed by enzyme-linked immunosorbent assays (ELISAs), multiplex arrays and flow cytometry. These analyses will identify the specific cytokines present at each of the three locations and identify differences in surface marker expression of ILC2s from each of these locations. Ultimately, by identifying ILC2 surface markers and cytokines which promote steroid-resistance, novel therapeutics which inhibit these markers and cytokines could be developed to treat EA.This work is very significant as asthma represents a significant economic healthcare burden and its incidence is predicted to rise in Canada. Development of novel EA therapeutics will allow for the treatment of steroid-resistant EA patients and improve the quality of life of these individuals."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428881
Name
Hosein Hannah
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of type-II innate lymphoid cells in allergic asthma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Asthma; Clinical; Eosinophils; Immunology; Lung Inflammation; Respiration
Abstract
"Emerging evidence suggests that eosinophilic asthma (EA) may be mediated by type-II innate lymphoid cells (ILC2s). Inflammatory cytokines produced by ILC2s promote eosinophil maturation. In EA, eosinophils migrate to the lungs and cause inflammation, driving pathogenesis. Corticosteroids are typically used to treat EA. However, 5-10% of asthmatics are resistant to this treatment and thus alternative therapeutics need to be developed. Recent work suggests that ILC2s can become resistant to steroids in the presence of specific cytokines. Thus, it is hypothesized that ILC2s may be responsible for the steroid insensitivity observed in some EA patients and that targeting of this cell population for inhibition could represent a novel therapeutic avenue for EA treatment.Currently, it is unknown which cytokines may promote ILC2 steroid resistance, and whether these cytokines influence ILC2 surface marker expression. Peripheral blood, sputum and bronchoalveolar lavage fluid collected from human subjects with EA will be analyzed by enzyme-linked immunosorbent assays (ELISAs), multiplex arrays and flow cytometry. These analyses will identify the specific cytokines present at each of the three locations and identify differences in surface marker expression of ILC2s from each of these locations. Ultimately, by identifying ILC2 surface markers and cytokines which promote steroid-resistance, novel therapeutics which inhibit these markers and cytokines could be developed to treat EA.This work is very significant as asthma represents a significant economic healthcare burden and its incidence is predicted to rise in Canada. Development of novel EA therapeutics will allow for the treatment of steroid-resistant EA patients and improve the quality of life of these individuals."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hosein, Hannah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~